Elevated CDKN2AIPNL expression correlated with poor overall survival in LIHC (HR = 1.7, p = 0.0026), UVM (HR = 26, p = 2.2e-6), BRCA (HR = 26, p = 2.2e-6), LUAD (HR = 1.36, p = 0.049), PCPG (HR = 1.71, p = 0.0012), and TGCT (HR = 0.37, p=0.023), and was associated with advanced tumor stages in metabolically active cancers. This evidence concerns the gene XTBD1 and neoplasm.